Research to improve NIBRG-14, to generate a library of pandemic candidate influenza vaccine viruses and corresponding reagents and to test novel pandemic vaccines all feature in the IRC research programme. IRC research is state-of-the-art and recognised internationally; it attracts outside funding from bodies such as:

• EU DG Research (for the rapid development of a pandemic vaccine strain through the project FLUPAN),

• UK Medical Research Council (MRC) (for improving antigen yield of pandemic vaccine strains),

• EU DG Research (for investigating novel pandemic vaccine strains through the project PANFLUVAC),

• EU DG Sanco (for developing a library of pandemic strains and reagents, on contract to project FLUSECURE).

• EU DG Research (for investigating novel pandemic vaccine strains through the project NASPANVAC),